GSK and Alfasigma ink agreement for worldwide rights for linerixibat
(Alliance News) - GSK PLC on Monday announced a global licence deal with Alfasigma Spa for the worldwide rights for linerixibat, an investigational treatment for cholestatic pruritus in primary biliary cholangitis. Read More